Angiogenesis inhibitory drug combination obtained according to a specific algorithm, preferably a FSC, in which an initial combination of drugs is iteratively adjusted. The drug combination according to the invention may advantageously comprise a RAPTA-C compound. In a more specific case the combination comprises RAPTA-C and eriotinib.
Titre
Drug Combination for Treatment of Proliferative Diseases
Date
2017
Note
Alternative title(s) :
(de) Arzneimittelkombination zur behandlung proliferativer krankheiten
(fr) Association de médicaments pour le traitement de maladies prolifératives
(en) Drug combination for treatment of proliferative diseases
Autres identifiant(s)
EPO Family ID: 52875103
Date de création de la notice
2017-05-02